RARX
RhumbLine Advisers’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-50,313
| Closed | -$2.42M | – | 3192 |
|
|
2020
Q1 | $2.42M | Buy |
50,313
+2,767
| +6% | +$133K | 0.01% | 1447 |
|
|
2019
Q4 | $2.23M | Buy |
47,546
+6,749
| +17% | +$317K | ﹤0.01% | 1744 |
|
|
2019
Q3 | $965K | Buy |
40,797
+2,712
| +7% | +$64.1K | ﹤0.01% | 2045 |
|
|
2019
Q2 | $1.15M | Buy |
38,085
+12,400
| +48% | +$373K | ﹤0.01% | 2003 |
|
|
2019
Q1 | $575K | Buy |
25,685
+4,960
| +24% | +$111K | ﹤0.01% | 2269 |
|
|
2018
Q4 | $377K | Buy |
20,725
+6,432
| +45% | +$117K | ﹤0.01% | 2429 |
|
|
2018
Q3 | $259K | Buy |
14,293
+164
| +1% | +$2.97K | ﹤0.01% | 2594 |
|
|
2018
Q2 | $141K | Buy |
14,129
+1,900
| +16% | +$19K | ﹤0.01% | 2826 |
|
|
2018
Q1 | $65K | Buy |
12,229
+1,490
| +14% | +$7.92K | ﹤0.01% | 2785 |
|
|
2017
Q4 | $91K | Sell |
10,739
-2,280
| -18% | -$19.3K | ﹤0.01% | 2787 |
|
|
2017
Q3 | $190K | Buy |
13,019
+185
| +1% | +$2.7K | ﹤0.01% | 2757 |
|
|
2017
Q2 | $241K | Buy |
+12,834
| New | +$241K | ﹤0.01% | 2665 |
|